Initial Trenching Returns up to 4.0 m at 3.10 g/t Au and 4.0 m at 2.68 g/t Au within Strong Geochemical Anomalies First-pass exploration confirms four robust gold-in-soil anomalies across…
-
-
Discovery of uranium mineralization in ideal geological setting, supported by regional radiometric anomaly, confirms large Rossing-style target ReeXploration Inc. (TSXV: REE) (FSE: K2I0) (‘ReeXploration’ or the ‘Company’) is pleased to…
-
Development-ready gold asset in premier mining jurisdiction with funded advancement plan; preparing to initiate project-development and exploration drill program Fortune Bay Corp. (TSXV: FOR,OTC:FTBYF) (FWB: 5QN) (OTCQB: FTBYF) (‘Fortune Bay’…
-
-
-
Investing
CHARBONE confirme le respect de l’echeancier de construction a Sorel-Tracy et annonce le debut imminent de la phase d’installation des equipements
(TheNewswire) Brossard, Quebec TheNewswire – le 12 novembre 2025 CORPORATION CHARBONE (TSXV: CH,OTC:CHHYF; OTCQB: CHHYF; FSE: K47) (« CHARBONE » ou la « Société »), un producteur et distributeur nord-américain…
-
Investing
CHARBONE Confirms Construction Schedule on Track at Sorel-Tracy and Announces the Imminent Start of Equipment Installation Phase
(TheNewswire) Brossard, Quebec TheNewswire – November 12, 2025 CHARBONE CORPORATION (TSXV: CH,OTC:CHHYF; OTCQB: CHHYF; FSE: K47) (‘ CHARBONE ‘ or the ‘ Company ‘), a North American producer and distributor…
-
Investing
Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States
Terra Clean Energy CORP. (‘ Terra ‘ or the ‘ Company ‘) (CSE: TCEC,OTC:TCEFF, OTCQB: TCEFF FSE: C 9O0) is pleased to announce that, further to its press release dated…
-
Mark Skousen of Forecasts & Strategies shares his outlook for gold, silver and the US economy. ‘We’ve entered an era of what I call permanent inflation,’ he explained. ‘After World…
-
Investing
InMed Pharmaceuticals: Innovating Cannabinoid-inspired Medicines, Backed by Real Revenue and Clear Path to Value
InMed Pharmaceuticals (NASDAQ: INM) pairs innovative therapeutic development in Alzheimer’s, ophthalmology, and dermatology with recurring revenue from its BayMedica manufacturing division — giving investors rare small-cap biotech exposure to high-impact…